


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Compounds of the~~ A compound of formula I



wherein

R¹ is H, OH, OA, CN, Hal, COR or CH₂R,

R is by OH, OA, NH₂, NHA or NA₂,

R² and R³ are H or A,

A is an alkyl group with 1–10 atoms,

X is O or S,

Hal is F, Cl, Br or I






n is 2-6,


m is 1-4

p is 0, 1, 2, 3 or 4


~~and their salts, enantiomers, solvates, racemates and other mixtures of enantiomers~~ or a salt, enantiomer, solvate, racemate or mixture of enantiomers thereof.

2. (Currently Amended) ~~Compounds~~ A compound according to claim 1, wherein R¹ is F or CN.
3. (Currently Amended) ~~Compounds~~ A compound according to claim 1, wherein R³ is H.
4. (Currently Amended) ~~Compounds~~ A compound according to claim 1, wherein X is S or O.
5. (Currently Amended) ~~Compounds~~ A compound according to claim 1, wherein p is 0 or 1 or 2 or 3 or 4.
6. (Currently Amended) ~~Indol derivatives~~ A compound according to claim 1 ~~selected from the following group of compounds~~ of the formula I1 to I5:







11




12



13



14



15

~~and their salts, solvates, enantiomers and racemates~~ or a salt, solvate, enantiomer or racemate thereof.

7. (Currently Amended) ~~Compounds of the~~ A pharmaceutical composition comprising a formula I according to Claim 1 and their ~~or physiologically acceptable salts or solvates as pharmaceutical active compounds~~ salt or solvate thereof and a pharmaceutically acceptable carrier.
8. (Cancelled)
9. (Currently Amended) ~~Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as~~ A method of inhibiting serotonin reuptake, comprising administering to a host in need thereof a compound according to claim 1 or a salt, solvate, enantiomer or mixture thereof~~inhibitor.~~
10. (Currently Amended) ~~Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates~~ A method of achieving a 5HT1A antagonists antagonistic effect, comprising administering to a host in need thereof a compound according to claim 1 or a salt, solvate, enantiomer or mixture thereof.
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Currently Amended) ~~Use of compounds according to Claim 1 and/or their physiologically acceptable salts or solvates, enantiomers or racemates for the production of a medicament~~ A method for the treatment of illnesses which can be

influenced by the binding of the compound of formula I to the 5-HT receptors,
comprising administering to a host in need thereof a compound according to claim 1
or a salt, solvate, enantiomer or mixture thereof.

15. (Currently Amended) ~~Use of compounds according to Claim 1 and/or their~~
~~physiologically acceptable salts or solvates, enantiomers or racemates for the~~
~~production of a medicament~~ A method for the treatment of illnesses of the central
nervous system, ~~in particular of mental disorders of the schizophrenia, or type and~~
for the control of psychotic anxiety states, comprising administering to a host in
need thereof a compound according to claim 1 or a salt, solvate, enantiomer or
mixture thereof.